Revolution Medicines, Inc. has disclosed preliminary information from its first-in-human examine of RMC-9805, an investigational drug concentrating on strong tumors…
Our selection of the week's biggest research news and features sent directly to your inbox. Enter your email address, confirm you're happy to receive our emails.